• Home
  • About
  • Team
  • Articles
  • Contact

Targeting Caspase-2 for the Treatment of Dementia.

by Myriel Team | Aug 18, 2026 | Reviews & Perspectives

Walters, M.A., Pockes, S., Ashe, K.H. (2026). Targeting Caspase-2 for the Treatment of Dementia. In: Wolfe, M.S. (eds) Advances in Drug Discovery for Alzheimer’s Disease. Topics in Medicinal Chemistry, vol 44. Springer, Cham. https://doi.org/10.1007/7355_2026_192...

The Molecular Implications of a Caspase-2-Mediated Site-Specific Tau Cleavage in Tauopathies

by Myriel Team | May 28, 2026 | Reviews & Perspectives

Liu P, Ashe KH. The Molecular Implications of a Caspase-2-Mediated Site-Specific Tau Cleavage in Tauopathies. Neural Regeneration Research. 2021;16(9):1774-1775. PMID: 33510072. DOI: https://doi.org/10.4103/1673-5374.306073 Summary This perspective article summarized...

Targeting Caspase-2 Interactions with Tau in Alzheimer’s Disease and Related Dementias

by Myriel Team | May 27, 2026 | Reviews & Perspectives

Pockes S, Walters MA, Ashe KH. Targeting Caspase-2 Interactions with Tau in Alzheimer’s Disease and Related Dementias. Translational Research. 2023;254:34-40. PMID: 36328077. DOI: 10.1016/j.trsl.2022.10.009.Summary This review synthesized evidence supporting...

Recent Posts

  • Targeting Caspase-2 for the Treatment of Dementia.
  • Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration
  • Caspase-2 Cleavage of Tau Reversibly Impairs Memory
  • Phosphorylation in Two Discrete Tau Domains Regulates a Stepwise Process Leading to Postsynaptic Dysfunction
  • Blocking Site-Specific Cleavage of Human Tau Delays Progression of Disease-Related Phenotypes in Genetically Matched Tau-Transgenic Mice Modeling Frontotemporal Dementia

Myriel Inc.
1000 Westgate Drive,
Suite 9150-E
Saint Paul MN 55114
Email Us

About

Team

Contact

Copyright 2026 Myriel Inc. | All Rights Reserved